Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Shares of Summit Therapeutics SMMT rose more than 15% on Friday after the analysts at Cantor Fitzgerald and Truist Securities ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Summit Therapeutics Inc.’s SMMT share price has surged by 5.60%, which has investors questioning if this is right time to sell.

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

that you should be aware of before investing here. NasdaqGM:SMMT Earnings Per Share Growth as at Apr 2025 Uncover the next big thing with financially sound penny stocks that balance risk and reward.

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other biotech stocks that dominate Monday’s top gainers. The stock market kicked off ...